## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.64 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (56% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($98.12)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Goldman Sachs Initiates Coverage of Revvity (RVTY) with Neutral Recommendation**
- Source: Nasdaq | 20251210T000857 | Neutral | Relevance: 98%
- Goldman Sachs has initiated coverage of Revvity (RVTY) with a Neutral recommendation. Analysts project an average one-year price target of $114.38/share for Revvity, indicating a potential 14.62% upside from its current price. Institutional ownership of Revvity remains strong, with several large investment firms holding significant stakes.

**2. Goldman Sachs initiates coverage on Revvity stock with Neutral rating By Investing.com**
- Source: Investing.com Canada | 20251209T080917 | Neutral | Relevance: 98%
-  Goldman Sachs has initiated coverage on Revvity Inc. (NYSE:RVTY) with a Neutral rating and a price target of $105.00, citing the company's significant exposure to early-stage biotech funding and China diagnostics markets, which are expected to remain challenging. Despite these headwinds, Goldman Sachs noted Revvity's company-specific growth drivers and a consumables-focused portfolio that could see a faster recovery. The investment bank anticipates that ongoing market challenges will temper the growth potential of Revvity's specific drivers, leading to limited upside for fiscal year 2026 estimates.

**3. Goldman Sachs initiates coverage on Revvity stock with Neutral rating By Investing.com**
- Source: Investing.com South Africa | 20251209T080837 | Neutral | Relevance: 97%
-  Goldman Sachs has initiated coverage on Revvity Inc. (NYSE:RVTY) with a Neutral rating and a price target of $105.00, implying a 5% upside. The firm cited Revvity's exposure to early-stage biotech funding and the China diagnostics market as potential headwinds, expecting these challenges to persist until 2026. Despite this, Goldman Sachs highlighted company-specific growth drivers that could largely offset these weaknesses, particularly a faster recovery for its consumables-focused portfolio if drug discovery activity increases.

**4. Goldman Sachs initiates coverage on Revvity stock with Neutral rating By Investing.com**
- Source: Investing.com Australia | 20251209T210851 | Neutral | Relevance: 97%
-  Goldman Sachs has initiated coverage on Revvity Inc. (NYSE:RVTY) with a "Neutral" rating and a $105.00 price target, suggesting a 5% upside. The firm cited Revvity's exposure to early-stage biotech funding and China diagnostics markets as challenges expected to persist through 2026. However, company-specific growth drivers, particularly its consumables-focused portfolio, are expected to largely offset these headwinds.

**5. Goldman Sachs initiates coverage on Revvity stock with Neutral rating**
- Source: Investing.com India | 20251209T082450 | Neutral | Relevance: 97%
-  Goldman Sachs has initiated coverage on Revvity Inc. (NYSE:RVTY) with a Neutral rating and a $105.00 price target, suggesting a 5% upside. The investment bank cited Revvity's exposure to early-stage biotech funding and China diagnostics markets as challenges, expecting them to persist until 2026. Despite these headwinds, Goldman Sachs believes company-specific growth drivers, particularly its consumables-focused portfolio, could largely offset potential weaknesses, though market headwinds are expected to dilute overall growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Volume divergence: price rising (+1.5% MRS) on declining volume (56% of avg) suggests distribution.
2. Elevated short interest (9.1%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +1.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.64 indicates undervaluation relative to growth. Forward P/E 19.6x stretched relative to 8% growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.1B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.64 |
| Forward P/E | 19.6 |
| Current P/E | 21.1 |
| YoY Growth | 7.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.9% to 2.4% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.6pp (needs >4.0% for momentum thesis). MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 4.6% shows strong absolute momentum above own 20MA. Outperforming sector by 4.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Volume at 56% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.38% (CS: 62) | Neutral |
| RSI_14 | 62.2 | Neutral |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.046x | Above |
| vs SMA50 | 1.085x | Above |
| vs SMA200 | 1.090x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $103.92
- **Stop Loss:** $98.12 (5.6% risk)
- **Target:** $115.52 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 237
- **Position Value:** $24,629.04
- **Portfolio %:** 24.63%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*